Delving into the Latest Updates on Universidad Autonoma Del Estado De Morelos with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

σ1 receptor(Sigma opioid receptor)	1

Cataracts are the leading cause of reversible blindness worldwide, primarily associated with the aggregation of proteins such as γ-crystallins, which are essential for maintaining lens transparency. Among these, human γD-crystallin (HγD) contains four conserved tryptophans, hypothesized to act as a protective mechanism against ultraviolet (UV) radiation. This study investigated the effects of low-dose UV-B radiation on HγD and its variants, in which each tryptophan was replaced by phenylalanine. The substitutions did not significantly affect the protein's secondary or tertiary structure but markedly reduced thermal stability, particularly in the W42F mutant. Aggregation kinetics were accelerated in all variants, with pronounced increases observed in the W130F and W156F mutants. Molecular dynamics simulations revealed that these substitutions disrupt hydrophobic interactions in both the N- and C-terminal domains, promoting instability and enhancing aggregation propensity. UV radiation induced chemical modifications, where Trp42 and Trp130 were the most affected, further driving aggregation. Changes in fluorescence spectra after UV exposure indicated the breakdown of the tryptophan indole ring and the formation of degradation products. These results confirm that tryptophans in HγD serve a crucial protective role against UV-induced damage by preserving structural stability and minimizing aggregation.

01 Jun 2025·Environmental Research

Effective photocatalytic chromium (VI) detoxification with metal-free heterojunction based on g-C3N5 and ZIF-8 carbon under visible light

Article

Author: Casales-Díaz, Maura ; Saldarriaga Noreña, Hugo Albeiro ; Ramos-Hernández, José Juan ; Reddy Bogireddy, Naveen Kumar ; Kesarla, Mohan Kumar ; Kar, Tathagata ; Román Abarca, María Esperanza ; Godavarthi, Srinivas

A metal-free heterojunction (CNZ8C) photocatalyst prepared using g-C₃N₅ (CN) and zeolitic imidazolate framework (ZIF)-derived carbon (Z8C) is reported for sequential reduction and elimination of toxic Cr (VI) from water. Recombination of photogenerated charge carriers in CN was evicted completely through heterojunction formation of CN with Z8C. This is evidenced from the transient photocurrent responses (TPR), photoluminescence (PL) measurements and electrochemical impedance spectroscopy (EIS). The band structure analysis from the valence band X-ray spectroscopy and diffused reflectance spectroscopy revealed that the synergy in the synthesized CN-Z8C heterojunction is responsible for the reduction of CN band gap. The experimental results obtained confirm that the positions of the valence and conduction bands are aligned to more negative values facilitating the Cr (VI) reduction. Incorporation of the highly conducting, porous CZ8 helps bring the Cr (VI) ions close to CN surface via adsorption that enhances the charge separation, favors the overall reduction and removal of reduced ions. The rate of reduction/removal significantly increased with CNZ8C 5:5 (with nearly 100% removal efficiency) heterojunction compared to that of CN. This heterojunction can be reutilized up to 5 cycles without any significant loss in efficiency. Mechanistic studies revealed that proper bandgap engineering leads to increased reduction and removal of chromium. The post treatment X-ray photoelectrons spectroscopy of the heterojunction confirms the +3 state of chromium. These observations suggest that the successful synergy between the CN and Z8C will bring new insights into chromium remediation.

01 Jun 2025·Leukemia Research

Identification of ZNF384 as a regulator of epigenome in leukemia

Article

Author: Ávila-López, Pedro A ; Martínez, Yamelie A ; Rojas, Francisco I Torres ; Ortíz-Ortíz, Julio ; Vargas, Laura C Zárraga ; Viguri, Gabriela E Campos

Leukemia is a complex hematologic cancer driven by genetic and epigenetic changes that impact gene expression. Understanding these molecular mechanisms is essential for improving leukemia diagnosis and prognosis. This study examines the role of the zinc finger protein ZNF384 in the epigenome and its influence on gene regulation in leukemia. We analyzed next-generation sequencing data from The Encyclopedia of DNA Elements (ENCODE), integrating datasets such as chromatin immunoprecipitation sequencing (ChIP-seq) of ZNF384 and regulatory histone marks, RNA sequencing (RNA-seq), and Hi-C data from K562 and GM12878 cells. Additionally, we used RNA-seq from K562 ZNF384 knock-down (KD) cells generated via CRISPR interference (CRISPRi) to validate our findings. This enabled us to explore the chromatin interaction patterns of ZNF384 and its regulatory impact. Our results demonstrate that ZNF384 associates with promoters and enhancers in K562 and GM12878 cells, facilitating increased transcription levels. We also found ZNF384 enriched at topologically associating domain (TAD) boundaries and chromatin loops, suggesting a role in three-dimensional (3D) chromatin organization. Furthermore, we identified a significant binding of ZNF384 at SINE-Alu elements in both K562 and GM12878 cells. In summary, this study highlights the regulatory role of ZNF384 in the leukemia epigenome and its impact on gene expression. Understanding the oncogenic implications of ZNF384 may improve leukemia diagnosis and prognosis.

100 Deals associated with Universidad Autonoma Del Estado De Morelos

Login to view more data

100 Translational Medicine associated with Universidad Autonoma Del Estado De Morelos

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Other

Login to view more data